CL2016002518A1 - Pharmaceutical combination of 8-cyclopropyl-3- [2- (3-fluorophenyl) ethyl] -7,8-dihydro-3h- [1,3] oxazino [6.5-g] [1,2,3] benzotriazine- 4,9-dione and an acetylcholinesterase inhibitor; pharmaceutical composition; and use for the treatment of cognitive disorders associated with brain aging and neurodegenerative diseases. - Google Patents

Pharmaceutical combination of 8-cyclopropyl-3- [2- (3-fluorophenyl) ethyl] -7,8-dihydro-3h- [1,3] oxazino [6.5-g] [1,2,3] benzotriazine- 4,9-dione and an acetylcholinesterase inhibitor; pharmaceutical composition; and use for the treatment of cognitive disorders associated with brain aging and neurodegenerative diseases.

Info

Publication number
CL2016002518A1
CL2016002518A1 CL2016002518A CL2016002518A CL2016002518A1 CL 2016002518 A1 CL2016002518 A1 CL 2016002518A1 CL 2016002518 A CL2016002518 A CL 2016002518A CL 2016002518 A CL2016002518 A CL 2016002518A CL 2016002518 A1 CL2016002518 A1 CL 2016002518A1
Authority
CL
Chile
Prior art keywords
oxazino
benzotriazine
dione
fluorophenyl
cyclopropyl
Prior art date
Application number
CL2016002518A
Other languages
Spanish (es)
Inventor
Sylvie Bretin
Maria Pueyo
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51383800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002518(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2016002518A1 publication Critical patent/CL2016002518A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Asociación entre la 8-ciclopropil-3-[2-(3-fluorofenil)etil]-7,8-dihidro-3h-[1,3]oxazino [6,5-g][1,2,3]benzotriazina-4,9-diona de fórmula (i) o una de sus sales de adición a un ácido o a una base farmacéuticamente aceptable y un inhibidor de la acetilcolinesterasa; composición farmacéutica y uso en el tratamiento de los trastornos cognitivos asociados con el alzheimerAssociation between 8-cyclopropyl-3- [2- (3-fluorophenyl) ethyl] -7,8-dihydro-3h- [1,3] oxazino [6.5-g] [1,2,3] benzotriazine- 4,9-dione of formula (i) or one of its addition salts to a pharmaceutically acceptable acid or base and an acetylcholinesterase inhibitor; Pharmaceutical composition and use in the treatment of cognitive disorders associated with Alzheimer's

CL2016002518A 2014-04-07 2016-10-04 Pharmaceutical combination of 8-cyclopropyl-3- [2- (3-fluorophenyl) ethyl] -7,8-dihydro-3h- [1,3] oxazino [6.5-g] [1,2,3] benzotriazine- 4,9-dione and an acetylcholinesterase inhibitor; pharmaceutical composition; and use for the treatment of cognitive disorders associated with brain aging and neurodegenerative diseases. CL2016002518A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1453046A FR3019464B1 (en) 2014-04-07 2014-04-07 NOVEL ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-G] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ACETYLCHOLINESTERASE INHIBITOR AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Publications (1)

Publication Number Publication Date
CL2016002518A1 true CL2016002518A1 (en) 2017-03-17

Family

ID=51383800

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002518A CL2016002518A1 (en) 2014-04-07 2016-10-04 Pharmaceutical combination of 8-cyclopropyl-3- [2- (3-fluorophenyl) ethyl] -7,8-dihydro-3h- [1,3] oxazino [6.5-g] [1,2,3] benzotriazine- 4,9-dione and an acetylcholinesterase inhibitor; pharmaceutical composition; and use for the treatment of cognitive disorders associated with brain aging and neurodegenerative diseases.

Country Status (19)

Country Link
US (1) US20170027949A1 (en)
EP (1) EP3129059A1 (en)
JP (1) JP2017510597A (en)
KR (1) KR20160134854A (en)
CN (1) CN106163563A (en)
AU (1) AU2015245416A1 (en)
CA (1) CA2944750A1 (en)
CL (1) CL2016002518A1 (en)
EA (1) EA201692006A1 (en)
FR (1) FR3019464B1 (en)
MA (1) MA39493A (en)
MD (1) MD20160115A2 (en)
MX (1) MX2016013118A (en)
PE (1) PE20170332A1 (en)
PH (1) PH12016501982A1 (en)
RU (1) RU2016143382A (en)
SG (1) SG11201608152RA (en)
WO (1) WO2015155451A1 (en)
ZA (1) ZA201606873B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005208871B2 (en) * 2004-01-26 2010-04-01 Cortex Pharmaceuticals Inc. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
SG163545A1 (en) * 2007-01-03 2010-08-30 Servier Lab 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
WO2009038752A2 (en) * 2007-09-20 2009-03-26 Cortex Pharmaceuticals, Inc. 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
MA39493A (en) 2015-10-15
ZA201606873B (en) 2018-11-28
CN106163563A (en) 2016-11-23
SG11201608152RA (en) 2016-11-29
WO2015155451A1 (en) 2015-10-15
EP3129059A1 (en) 2017-02-15
US20170027949A1 (en) 2017-02-02
AU2015245416A1 (en) 2016-10-27
RU2016143382A (en) 2018-05-07
JP2017510597A (en) 2017-04-13
PH12016501982A1 (en) 2017-01-09
KR20160134854A (en) 2016-11-23
EA201692006A1 (en) 2017-02-28
FR3019464B1 (en) 2016-05-06
FR3019464A1 (en) 2015-10-09
MX2016013118A (en) 2017-01-20
CA2944750A1 (en) 2015-10-15
PE20170332A1 (en) 2017-04-15
MD20160115A2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
CY1121413T1 (en) DIHYDROPYRROLOPYRIDINE ROR-GAMMA INHIBITORS
ECSP19028657A (en) DERIVATIVES OF 6,7,8,9-TETRAHIDRO-3H-PIRAZOLO [4,3-F] ISOQUINOLINE USEFUL IN THE TREATMENT OF CANCER
CR20160523A (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE TO TREAT CANCER
MX2018009257A (en) Benzimidazole derivatives as modulators of ror-gamma.
CL2014001752A1 (en) Substituted bicyclic compounds; pharmaceutical composition that includes them; and use in the treatment of diseases such as cancer, Alzheimer's, AIDS, among others.
BR112015020389A2 (en) carbazole compounds useful as bromodomain inhibitors
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
CL2016002091A1 (en) Triazine compound and its use for medicinal purposes
AR090241A1 (en) INHIBITORS OF THE B-SECRETASE
UY35628A (en) ? HETEROAROMATIC COMPOUNDS AND ITS USE AS DOPAMINE DIGINAL LINKS ?.
UY36677A (en) TRICYCLIC COMPOUNDS AS ANTINEOPLASTIC AGENTS
DOP2015000214A (en) NEW INHIBITING COMPOUNDS OF TYPE 10A PHOSPHODIESTERASE
UY35746A (en) SUBSTITUTED PHENYLALANINE DERIVATIVES
CL2017000827A1 (en) Aldosterone synthase inhibitors
CR20160527A (en) CARBOXAMIDE DERIVATIVES
DOP2016000297A (en) PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT INFECTIOUS DISEASES
AR092247A1 (en) INHIBITORS OF THE B-SECRETASE
UY36228A (en) HETEROARILO DERIVATIVES AS INHIBITORS OF ALDOSTERONE SINTASA (CYP11B2) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CO2018007436A2 (en) Alkyl dihydroquinolinsulfonamide compounds
CL2016001024A1 (en) Compounds derived from pyrido [4,3-b] pyrazin-2-carboxamides; preparation procedure; Pharmaceutical composition and use for the treatment of neurodegenerative disorders, schizophrenia, depression, among other diseases.
UY36732A (en) PIRIDIN PIRAZINONAS NOVEDOSAS AS BROMODOMINIUM INHIBITORS OF THE BET FAMILY
CL2016002518A1 (en) Pharmaceutical combination of 8-cyclopropyl-3- [2- (3-fluorophenyl) ethyl] -7,8-dihydro-3h- [1,3] oxazino [6.5-g] [1,2,3] benzotriazine- 4,9-dione and an acetylcholinesterase inhibitor; pharmaceutical composition; and use for the treatment of cognitive disorders associated with brain aging and neurodegenerative diseases.
CO2017000211A2 (en) Compounds, pharmaceutical composition and their use in the treatment of neurodegenerative diseases
CY1121690T1 (en) QUINOLYL-HYDRAZONES FOR THE TREATMENT OF TUBERCULOSIS AND RELATED DISEASES
PH12017501248A1 (en) New association between 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione and an antidepresant and pharmaceutical compositions containing it